Related Experiment Videos
The p53-deficient mouse: a model for basic and applied cancer studies
1Division of Molecular Virology, Baylor College of Medicine, Houston, TX 77030, USA.
Abstract:
Inactivation of the p53 gene in the germline of mice by gene targeting has provided researchers with a model similar in many respects to the analogous human inherited cancer predisposition Li-Fraumeni syndrome. The viability of p53 null mice has allowed unexpected opportunities to study the role of p53 in many different in-vivo and in-vitro contexts. Null (p53-/-) mice have an average time to tumor development of 4.5 months, while half of the heterozygous (p53+/-) mice develop tumors by 18 months. The p53-deficient mice have been particularly valuable in examining the effects of p53 loss on tumor progression. In addition, the mice hold significant promise as tools to assess carcinogens, teratogens, chemopreventative agents, and cancer therapeutic regimens.
Insights
Gene targeting in mice created a p53 model for Li-Fraumeni syndrome. These p53-deficient mice are crucial for studying cancer progression and evaluating potential cancer treatments.
Area of Science:
- Genetics and Genomics
- Cancer Biology
- Animal Models
Background:
- The p53 tumor suppressor gene plays a critical role in preventing cancer.
- Germline inactivation of p53 leads to Li-Fraumeni syndrome in humans, a rare inherited cancer predisposition.
- Studying p53 function in vivo is essential for understanding cancer development.
Purpose of the Study:
- To investigate the role of p53 in cancer development and progression using a mouse model.
- To establish a preclinical tool for evaluating carcinogens, teratogens, and therapeutic agents.
- To analyze the impact of p53 loss on tumor formation and growth dynamics.
Main Methods:
- Gene targeting to create p53 germline inactivation in mice.
- Phenotypic analysis of p53 null (p53-/-) and heterozygous (p53+/-) mice.
- Tumor development monitoring and characterization.
Main Results:
- p53 null mice exhibit significantly accelerated tumor development (average 4.5 months).
- p53 heterozygous mice show a higher incidence of tumors by 18 months compared to wild-type.
- p53-deficient mice provide a valuable platform for studying tumor progression.
Conclusions:
- p53-deficient mice serve as a robust model for Li-Fraumeni syndrome and inherited cancer predisposition.
- These mice are instrumental in understanding the in vivo functions of p53 in cancer suppression.
- The p53 mouse model offers significant potential for preclinical assessment of cancer-related agents and therapies.